Acadia History

For more than 25 years, we have delivered on the promise of science to blaze new trails in  research and development to deliver new treatment options to help address the unmet need.
 

 25+ Years of Innovation and Trailblazing

For more than 25 years, we have been trailblazing solutions for people with neurological conditions. The Acadia family is committed to fulfilling the promise of science to deliver vital solutions to those most in need.

Explore our journey and learn how we forge a healthy future for fuller, brighter lives.

2022

Acadia and Stoke Therapeutics collaborate to pursue multiple RNA-based treatments for severe and rare genetic neurodevelopmental diseases.

Acadia resubmitted supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin), narrowing the proposed indication from dementia-related psychosis to Alzheimer’s disease psychosis. FDA has assigned a Target action date of August 4, 2022, and the FDA’s Division of Psychiatry is planning to hold an Advisory committee meeting on June 17 in connection with its review.

2021

New England Journal of Medicine publishes results from the Phase 3 HARMONY study evaluating pimavanserin in patients with dementia-related psychosis.

Acadia reports positive top-line results from the Phase 3 Lavender™ study evaluating trofinetide, an investigational drug for the treatment of Rett syndrome.*

2020

Acadia acquires CerSci Therapeutics, adding novel pain program to portfolio.

Acadia and Neuren Pharmaceuticals announce rare pediatric disease designation for trofinetide for the treatment of Rett syndrome.*

Acadia and Vanderbilt University announce an exclusive license agreement and research collaboration to develop and commercialize novel drug candidates targeting the muscarinic M1 receptor with the potential to treat a range of central nervous system disorders.

Acadia submits a Supplemental New Drug Application to the U.S. FDA for NUPLAZID® (pimavanserin), for the treatment of hallucinations and delusions associated with dementia-related psychosis. FDA accepts our application.

2019

Acadia initiates Phase 3 CLARITY program with pimavanserin as adjunctive treatment for major depressive disorder.

Acadia presents positive top-line results from pivotal Phase 3 HARMONY trial of pimavanserin in patients with dementia-related psychosis at 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting.

Acadia announces positive top-line results from Phase 2 ADVANCE trial of pimavanserin as treatment for negative symptoms of schizophrenia.

Acadia initiates Phase 3 pivotal study of trofinetide in Rett syndrome*, a rare neurodevelopment CNS disorder.

2018

Acadia reports positive top-line results from Phase 2 CLARITY trial of pimavanserin as adjunctive treatment for major depressive disorder.

Acadia signs exclusive North American license agreement for the development and commercialization of trofinetide for Rett syndrome.*

FDA approves new dosing formulation and strength for NUPLAZID® (pimavanserin).

Phase 2 study evaluating pimavanserin in patients Alzheimer’s disease psychosis published in The Lancet Neurology.

2017

FDA grants Breakthrough Therapy Designation (BTD) to pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis.

Acadia is named one of Forbes’ “Most Innovative Growth Companies” (#11 of 100).

2016

FDA Approves NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis.

Acadia reports positive Phase 2 data for pimavanserin in patients with Alzheimer’s disease psychosis.

Acadia initiates ENHANCE Phase 3 trial with pimavanserin as adjunctive treatment for schizophrenia with inadequate response to current antipsychotic treatment.

Acadia initiates ADVANCE Phase 2 trial with pimavanserin as adjunctive treatment for negative symptoms of schizophrenia.

Acadia is added to Large-Cap Russell 1000 Index.

2015

New Drug Application (NDA) for NUPLAZID® (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Parkinson’s Disease Psychosis Accepted and Granted Priority Review by the FDA.

Steve Davis is appointed as President and Chief Executive Officer.

2014

Acadia receives FDA Breakthrough Therapy Designation for NUPLAZID® (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

2013

Acadia announces publication in The Lancet of pivotal Phase 3 Parkinson’s disease psychosis trial with pimavanserin.

Acadia is added to the NASDAQ Biotechnology and the Russell 2000 indices.

Acadia meets with the FDA, then announces an expedited path to a New Drug Application filing with pimavanserin for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.

Acadia announces presentation of data from Phase 3 trial with pimavanserin for Parkinson’s disease psychosis at the American Academy of Neurology Annual Meeting.

2012

Acadia reports positive Phase 3 data for pimavanserin in patients with Parkinson’s disease psychosis.

2010

Acadia initiates a pivotal Phase 3 efficacy, tolerability and safety study with pimavanserin in patients with Parkinson’s disease psychosis.

Acadia regains full worldwide rights to pimavanserin following the conclusion of its collaboration with Biovail.

2009

Acadia forms collaboration with Biovail to develop and commercialize pimavanserin in North America.

2007

Acadia reports positive Phase 2 data for pimavanserin as a co-therapy for patients with schizophrenia.

2006

Acadia reports positive Phase 2 data for pimavanserin in patients with Parkinson’s disease psychosis.

2004

Acadia completes its initial public offering and trades under the symbol “ACAD” on the NASDAQ Stock Market.

2001

Pimavanserin first synthesized.

Pimavanserin is synthesized by an Acadia chemist working in the Copenhagen facility. 

1999

Our scientists start a project to discover new non-dopaminergic antipsychotic agents selectively acting as inverse agonists on the 5-HT2A receptor.

1997

Company name changed to Acadia Pharmaceuticals Inc.

Inspired by the power and beauty of Acadia National Park, the company rebrands.

We shift our focus to developing our own portfolio of product candidates.

Our headquarters moves from Winooski, Vermont, to the biotech hub of San Diego, California

Our medicinal chemistry operations are established in Copenhagen, Denmark—supported by Danish investors.

Acadia establishes its first of several drug discovery and development collaborations with Allergan.

1993

Company founded.

Receptor Technologies is founded by Mark Brann, Ph.D., a professor at the University of Vermont.

The company starts by working with major pharmaceutical companies to perform high-throughput screening based on its proprietary functional genomics platform, R-SAT.







Important Disclosures

*The safety and efficacy of the investigational agent(s) listed above have not been established or approved by the U.S. Food and Drug Administration (FDA). 
The safety and efficacy of the investigational use of NUPLAZID® (pimavanserin) have not been established or approved by the FDA. For NUPLAZID’s FDA-approved indication, please read the full Prescribing Information, including Boxed WARNING.